Browsing by Author Mylonakis, N.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 9 to 14 of 14 < previous 
TitleAuthor(s)Issue date???itemlist.???
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group studyBriasoulis, E.; Fountzilas, G.; Bamias, A.; Dimopoulos, M. A.; Xiros, N.; Aravantinos, G.; Samantas, E.; Kalofonos, H.; Makatsoris, T.; Mylonakis, N.; Papakostas, P.; Skarlos, D.; Varthalitis, I.; Pavlidis, N.24-Nov-2015-
Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG)Kosmidis, P.; Mylonakis, N.; Skarlos, D.; Samantas, E.; Dimopoulos, M.; Papadimitriou, C.; Kalophonos, C.; Pavlidis, N.; Nikolaidis, C.; Papaconstantinou, C.; Fountzilas, G.24-Nov-2015-
Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized studyKosmidis, P.; Mylonakis, N.; Fountzilas, G.; Samantas, E.; Athanassiadis, A.; Pavlidis, N.; Skarlos, D.24-Nov-2015-
Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II studyKosmidis, P. A.; Mylonakis, N.; Fountzilas, G.; Samantas, E.; Athanasiadis, A.; Andreopoulou, E.; Pavlidis, N.; Skarlos, D.24-Nov-2015-
A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) studyKalofonos, H. P.; Nicolaides, C.; Samantas, E.; Mylonakis, N.; Aravantinos, G.; Dimopoulos, M. A.; Gennatas, C.; Kouvatseas, G.; Giannoulis, E.; Dervenis, C.; Basdanis, G.; Pavlidis, N.; Androulakis, I.; Fountzilas, G.24-Nov-2015-
A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology GroupKosmidis, P.; Mylonakis, N.; Fountzilas, G.; Pavlidis, N.; Samantas, E.; Karabelis, A.; Kattis, K.; Skarlos, D.24-Nov-2015-